通过分析药物,疾病和基因之间的网络,为非酒精性脂肪性肝病重新定位药物
Md Altaf-Ul-Amin1, Ahmad Kamal Nasution1, Rumman Mahfujul Islam1
1Computational Systems Biology Lab, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, Japan.
Metabolites
|April 25, 2025
概括
本研究通过分析药物向网络和疾病相似性来确定非酒精性脂肪性肝病 (NAFLD) 的潜在药物重用候选人. 这些发现加速了新的NAFLD治疗开发.
科学领域:
- 计算生物学是一种计算生物学.
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
背景情况:
- 对非酒精性脂肪肝 (NAFLD) 等复杂疾病的药物开发是耗时且昂贵的.
- 药物重新定位为传统药物发现提供了一个更快,更经济的替代方案.
- 确定现有药物的新用途可以加速治疗的进步.
研究的目的:
- 为了确定NAFLD的潜在药物重用候选人.
- 为药物发现利用疾病与疾病的关系和药物向数据.
- 加速开发新的NAFLD治疗方法.
主要方法:
- 构建了一个双边的药物网络及其目标基因.
- 应用了BiClusO双集群算法来识别相关的集群.
- 基于与NAFLD风险基因的关联和疾病相似性的预测候选药物.
主要成果:
- 开发了一种新的排名方法来优先考虑候选药物.
- 通过全面的文献审查评估候选人的有效性.
- 确定了用于NAFLD治疗的有前途的重用药物.
结论:
- 药物重定向显示出加速NAFLD治疗发展的巨大潜力.
- 这种方法为复杂疾病的新型治疗策略提供了宝贵的见解.
- 这项研究强调了计算方法在药物发现中的有效性.
相关概念视频
Drug Discovery: Overview
7.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.1K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Structure-Activity Relationships and Drug Design
437
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
437
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
14
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
14
Drug Biotransformation: Overview
2.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.2K


